SoftOx Biofilm Eradicator (SBE) study is published

A peer-reviewed article describing a study investigating the safety and tolerability as well as wound size effect and antimicrobial efficacy of SOftOx Biofilm Eradicator has just been accepted by the top ranked medical wound journal “Advances in Wound Care”. “The conclusion in the study is very interesting. It shows SBE is safe and tolerable in humans. In addition SBE reduced the bioburden and strongly improved wound closure”, says Thomas Bjarnsholt, professor at Copenhagen University. A first-in-human clinical study investigating the safety and tolerability of stabilized hypochlorous acid in patients with chronic leg ulcers | Advances in Wound Care (liebertpub.com) Link to the published article: https://www.liebertpub.com/doi/10.1089/wound.2024.0040?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed About SoftOx Solutions AS: SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian medtech/biotech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com More information: Access the news on Oslo Bors NewsWeb site

The release as fetched from its publisher. soft-ox.com ↗